The latest from BioStock
» Fast Track for Vicore Pharma's pulmonary fibrosis candidate
» Toleranzia has responded to EMA's feedback
» Elicera CEO: "All signs of the disease have disappeared in the first patient"
» Report rush for Getinge
» BiBBInstruments CEO: "First order sends positive signals"
Read the newsletter for v.4 here.
The latest news
announces that the FDA has granted Fast Track Designation for the company's drug candidate buloxibutide for the treatment of idiopathic pulmonary fibrosis. Read more.
Alligator Bioscience announces publication of clinical data for ATOR-1017 (unpublished) in the Journal for ImmunoTherapy of Cancer. Read moreThe subscription period for the company's rights issue begins today. Read more.
Qlife carries out a rights issue of approximately SEK 11,8 million and enters into an agreement for a credit facility of SEK 5,6 million. Read more.
Alteco Medical applies for delisting following a request for compulsory redemption of shares from Anders Althin. Read more.
Alzinova's The CMO is stepping down from his role so that the company can appoint a CMO on site at the company's headquarters in Gothenburg. Read more.
Diagonal Bio presents positive pilot test results and secures an order from StallZet. Read more.
Magnasense terminates the agreement with Digital Health Solutions. Read more.
Invitation
Ambea Revenio Group sectra Sedana Medical
Reports
General Meeting
Brain+ Chordate Medical Lipigon Pharmaceuticals
This morning's price development
Index: OMXS30 +0,7% Healthcare: + 0,6 %
| Winner | Förlorare |
| Double Bond Pharmaceutical +14,6% | Qlife -28,3% |
| Carbiotix +13,7% | Bio Vitos -14,2% |
| Elicera Therapeutics +11,1% | Audience -9% |
| Abera Bioscience +9,6% | Polymer Factory -8% |
| Odinwell +9,6% | 2cureX -7,3% |